Eisai to Use BioSeek's Drug Modeling Platform

May 04, 2010

NEW YORK (GenomeWeb News) – Asterand subsidiary BioSeek will collaborate on multiple oncology and inflammation-focused projects with the Japanese pharmaceutical company Eisai, Asterand said today.

Under the two-year agreement, the BioMap platform, which includes cell-based models designed to replicate interactions that are found in pharmacology and toxicology, will be used in research projects in both the US and Japan.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Dual Listings Sought

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

Allocating the Grant Pie

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

More Proposed for NSF

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

This Week in PNAS

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.

Featured White Papers

Application of the Megaruptor for Shearing of Ultra-Long DNA Fragments in the Context of Long Read Sequencing using Third-Gen Sequencing Technologies

Megaruptor Genomic DNA Shearing for Large Insert Sequencing Library Preparation

What to Look for in an Informatics Platform for Biologics R&D

STARLIMS Quality Manufacturing Solution Interfacing with 3rd party systems

Jun

26

Featured Webinar

The Landscape of Alternative Polyadenylation in the Lung Cancer Transcriptome

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.

Main menu